Targeted Diagnostics
Early detection and monitoring of neurodegenerative and neurodevelopmental disorders, healthy aging
Targeted approach: brain-enriched microRNA biomarkers in plasma
Collaborations with academia, medical centers, disease foundations and industry
Peer-reviewed publications, grant awards, patents
Technology
At DiamiR, we focus on the development and commercialization of an innovative technology based on analysis of brain-enriched microRNA biomarkers in blood plasma to be used for screening, early and differential diagnosis, enrollment of better defined participants into clinical trials, as well as disease progression and treatment monitoring.
Leadership
Kira Sheinerman, PhD, MBA
Co-Founder & Executive Director
Alidad Mireskandari, PhD, MBA
Chief Executive Officer
Samuil Umansky, MD, PhD, Dr Sci
Co-Founder & Chief Scientific Officer
Gyanendra Kumar, PhD
VP, Assay Development
Kenny K. Ablordeppey, MS
Laboratory Supervisor & Project Manager
Gary Anthony
Acting Chief Financial Officer
Advisory Board
Henry (Harv) M. Rinder, MD, MA, FACP, FASCP
Professor of Laboratory Medicine & Internal Medicine (Hematology)
Yale School of Medicine & Yale-New Haven Hospital
Robert Rissman, PhD
Professor of Neurosciences at the University of California San Diego (UCSD)
Research Biologist at VA San Diego
Founding Director of UCSD’s Alzheimer's Disease Cooperative Study Biomarker Core
Founding Director of the Biomarker Core for University of Southern California Alzheimer’s Therapeutic Research Institute
Director of UCSD’s Shiley-Marcos Alzheimer’s Disease Research Center Neuropathology and Biomarker Cores and Brain Bank and the Alzheimer’s Clinical Trials Consortium
Mikhail Denissenko, MD, PhD
Advisor
